These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

529 related articles for article (PubMed ID: 30336824)

  • 1. Effect of Evolocumab on Coronary Plaque Composition.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE
    J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV).
    Puri R; Nissen SE; Somaratne R; Cho L; Kastelein JJ; Ballantyne CM; Koenig W; Anderson TJ; Yang J; Kassahun H; Wasserman SM; Scott R; Borgman M; Nicholls SJ
    Am Heart J; 2016 Jun; 176():83-92. PubMed ID: 27264224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJ; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Scott R; Ungi I; Podolec J; Ophuis AO; Cornel JH; Borgman M; Brennan DM; Nissen SE
    JAMA; 2016 Dec; 316(22):2373-2384. PubMed ID: 27846344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.
    Nicholls SJ; Kataoka Y; Nissen SE; Prati F; Windecker S; Puri R; Hucko T; Aradi D; Herrman JR; Hermanides RS; Wang B; Wang H; Butters J; Di Giovanni G; Jones S; Pompili G; Psaltis PJ
    JACC Cardiovasc Imaging; 2022 Jul; 15(7):1308-1321. PubMed ID: 35431172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of the GLAGOV trial.
    Nissen SE; Nicholls SJ
    Cleve Clin J Med; 2017 Dec; 84(12 Suppl 4):e1-e5. PubMed ID: 29281604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
    Liang D; Li C; Tu Y; Li Z; Zhang M
    Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implications of GLAGOV study.
    Nicholls SJ; Puri R
    Curr Opin Lipidol; 2017 Dec; 28(6):465-469. PubMed ID: 28937411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of evolocumab therapy on coronary fibrous cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome.
    Yano H; Horinaka S; Ishimitsu T
    J Cardiol; 2020 Mar; 75(3):289-295. PubMed ID: 31495548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interindividual Variation in Low-Density Lipoprotein Cholesterol Level Reduction With Evolocumab: An Analysis of FOURIER Trial Data.
    Qamar A; Giugliano RP; Keech AC; Kuder JF; Murphy SA; Kurtz CE; Wasserman SM; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2019 Jan; 4(1):59-63. PubMed ID: 30540337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combining evolocumab with statin on carotid intraplaque neovascularization in patients with premature coronary artery disease (EPOCH).
    Han Y; Ren L; Fei X; Wang J; Chen T; Guo J; Wang Q
    Atherosclerosis; 2024 Apr; 391():117471. PubMed ID: 38493669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention: The Multicenter Randomized Controlled PRECISE-IVUS Trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Am Coll Cardiol; 2015 Aug; 66(5):495-507. PubMed ID: 26227186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic effect of ezetimibe addition on coronary atheroma regression in patients with prior statin therapy: Subanalysis of PRECISE-IVUS trial.
    Tsujita K; Yamanaga K; Komura N; Sakamoto K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    Eur J Prev Cardiol; 2016 Sep; 23(14):1524-8. PubMed ID: 27296705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.
    Stroes E; Colquhoun D; Sullivan D; Civeira F; Rosenson RS; Watts GF; Bruckert E; Cho L; Dent R; Knusel B; Xue A; Scott R; Wasserman SM; Rocco M;
    J Am Coll Cardiol; 2014 Jun; 63(23):2541-2548. PubMed ID: 24694531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plaque REgression with Cholesterol absorption Inhibitor or Synthesis inhibitor Evaluated by IntraVascular UltraSound (PRECISE-IVUS Trial): Study protocol for a randomized controlled trial.
    Tsujita K; Sugiyama S; Sumida H; Shimomura H; Yamashita T; Yamanaga K; Komura N; Sakamoto K; Ono T; Oka H; Nakao K; Nakamura S; Ishihara M; Matsui K; Sakaino N; Nakamura N; Yamamoto N; Koide S; Matsumura T; Fujimoto K; Tsunoda R; Morikami Y; Matsuyama K; Oshima S; Kaikita K; Hokimoto S; Ogawa H;
    J Cardiol; 2015 Oct; 66(4):353-8. PubMed ID: 25577723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of maximally intensive statin therapy on changes in coronary atheroma composition: insights from SATURN.
    Puri R; Libby P; Nissen SE; Wolski K; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Raichlen JS; Uno K; Kataoka Y; Tuzcu EM; Nicholls SJ
    Eur Heart J Cardiovasc Imaging; 2014 Apr; 15(4):380-8. PubMed ID: 24448227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PCSK9 Inhibitor causes a decrease in the level of oxidatively modified low-density lipoproteins in patients with coronary artery diseases.
    Lankin VZ; Tikhaze AK; Viigimaa M; Chazova IЕ
    Ter Arkh; 2018 Sep; 90(9):27-30. PubMed ID: 30701731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PCSK9 and Coronary Artery Plaque-New Opportunity or Red Herring?
    Barbieri L; Tumminello G; Fichtner I; Corsini A; Santos RD; Carugo S; Ruscica M
    Curr Atheroscler Rep; 2024 Oct; 26(10):589-602. PubMed ID: 39150672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [What has the GLAGOV clinical study shown?].
    Murín J
    Vnitr Lek; 2017; 63(5):329-332. PubMed ID: 28726431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.